The Swedish company Karo Bio, listed on the OMX Nordic Exchange Stockholm 1998 (Reuters: KARO. ST), today announced that Wyeth (NYSE:WYE) and Karo Bio extended their atherosclerosis collaboration for an additional year until August 31, 2009. The primary objective of the extension is to identify and select development candidates for treatment of atherosclerosis and to further evaluate additional...

Karo Bio has successfully completed a 12 week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on statin treatment. Data show that eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein (a) and was safe and well tolerated. The data...

The Karo Bio Research Foundation supports academic research within the field of Karo Bio’s research activities. The first two grants were awarded late 2007 and recently two additional applications have been granted research funding.

At Karo Bio AB’s annual general meeting on Friday April 25, 2008 the following was resolved.

Karo Bio’s compound, KB3305, for treatment of type 2 diabetes, shows robust and predictable pharmacokinetics and the subjects are well exposed without serious adverse events in the first phase I clinical study.

The Karo Bio annual report for 2007 is available on the company’s web site as of today, at www. karobio. com

Karo Bio initiates the second clinical phase IIb dose ranging study with eprotirome. This study will be conducted in dyslipidemia patients receiving concomitant treatment with the cholesterol absorption inhibitor ezetimibe. The first phase IIb study in 180 patients where eprotirome is given in addition to statin treatment is progressing according to plan.

The annual general meeting of the shareholders of Karo Bio Aktiebolag (publ) will be held on Friday April 25, 2008 at 2.00 p. m. in Wenströmsalen, IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

In September 2006 Karo Bio and Radius announced a licensing agreement in which Radius acquired the exclusive worldwide rights to a new class of selective androgen receptor modulators (SARMs) developed by Karo Bio. Karo Bio has now reacquired the full rights to these compounds and to all related data generated by Radius.

The year in brief• Net sales amounted to MSEK 7.5 (44.0) • Net loss amounted to MSEK 203.4 (126.1) • Loss per share amounted to SEK 1.92 (1.38)• Cash flow from operating activities amounted to MSEK -178.3 (-110.4). Cash, cash equivalents and other short-term investments totaled MSEK 432.3 (231.0) at December 31, 2007 • A rights issue generating net proceeds of MSEK 387.2 was completed in the...

Karo Bio and Zydus Cadila, one of India’s leading healthcare companies, have initiated a three year research collaboration with the purpose to discover and develop novel, selective glucocorticoid receptor (GR) modulators for the treatment of inflammatory diseases.

 Eprotirome approved as generic name for KB2115 The continued clinical development of eprotirome is progressing according to plan. All patients in a new phase IIb study have been enrolled and the dosing has been initiated Important scientific data from Karo Bio’s first clinical study with eprotirome was recently published in the American Journal Proceedings of the National Academy of Sciences...